Compugen Ltd.

Compugen Ltd. is a clinical-stage therapeutic discovery and development company headquartered in Holon, Israel, with additional offices in South San Francisco, California. Incorporated in Israel in 1993, the company leverages a predictive computational discovery platform to identify novel drug targets and develop cancer immunotherapies. Its mission is to discover new drug targets and create treatments that expand the efficacy and reach of immunotherapies.

The company's primary focus is on immuno-oncology and autoimmune diseases. Key product candidates in its pipeline include COM701 (PVRIG), COM902 (TIGIT), BAY 1905254 (ILDR2), and CGEN-15001/ILDR2 Fc Fusion. Compugen has established strategic collaborations, including agreements with Bristol-Myers Squibb to evaluate COM701 in combination with Opdivo, with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products, and with Gilead Sciences, Inc. for COM503 and other products.

Eran Ophir serves as the President and CEO, with Anat Cohen-Dayag as Chairman. Recent activities include being on track for the interim analysis of its COM701 MAIA-ovarian trial and presenting an ovarian cancer trial poster at the ESMO Gynaecological Cancers Congress 2026. The company also participated in a Jones Trading Fireside Chat Series focused on AI/ML-based drug development. Compugen reported its Q1 2026 earnings, noting an expanded net loss and revenue figures that lagged estimates.